Liu Y, Li C, Deng W
Clin Cosmet Investig Dermatol. 2025; 18():47-59.
PMID: 39802668
PMC: 11725243.
DOI: 10.2147/CCID.S500654.
Elguindy M, Young J, Ho W, Lu R
J Immunother Cancer. 2024; 12(12.
PMID: 39631850
PMC: 11624716.
DOI: 10.1136/jitc-2024-009175.
Chen Y, Wang K, Zhang X, Tao D, Shang Y, Wang P
J Physiol Biochem. 2024; .
PMID: 39546272
DOI: 10.1007/s13105-024-01061-8.
Liu Y, Zhou F, Ali H, Lathia J, Chen P
Cell Mol Immunol. 2024; 21(12):1354-1375.
PMID: 39406966
PMC: 11607068.
DOI: 10.1038/s41423-024-01226-x.
Amin T, Hossain A, Jerin N, Mahmud I, Rahman M, Islam S
Cancer Control. 2024; 31:10732748241290067.
PMID: 39353594
PMC: 11459535.
DOI: 10.1177/10732748241290067.
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside.
Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S
Exp Hematol Oncol. 2024; 13(1):72.
PMID: 39085965
PMC: 11292955.
DOI: 10.1186/s40164-024-00539-x.
Non-genetic heterogeneity and immune subtyping in breast cancer: Implications for immunotherapy and targeted therapeutics.
Hassan M, Tutar L, Sari-Ak D, Rasul A, Basheer E, Tutar Y
Transl Oncol. 2024; 47:102055.
PMID: 39002207
PMC: 11299575.
DOI: 10.1016/j.tranon.2024.102055.
Extracellular vesicles originating from melanoma cells promote dysregulation in haematopoiesis as a component of cancer immunoediting.
Mamand D, Bazaz S, Mohammad D, Liang X, Pavlova S, Mim C
J Extracell Vesicles. 2024; 13(7):e12471.
PMID: 38944672
PMC: 11214607.
DOI: 10.1002/jev2.12471.
ACTL6A: unraveling its prognostic impact and paving the way for targeted therapeutics in carcinogenesis.
Eid R, Mamdouh F, K Abdulsahib W, Alshaya D, Al-Salmi F, Ali Alghamdi M
Front Mol Biosci. 2024; 11:1387919.
PMID: 38872915
PMC: 11170035.
DOI: 10.3389/fmolb.2024.1387919.
Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma.
Alharthi S, Alavi S, Nisa M, Koohi M, Raza A, Ebrahimi Shahmabadi H
Pharm Res. 2024; 41(6):1163-1181.
PMID: 38839718
DOI: 10.1007/s11095-024-03722-1.
Fluid-Dynamic Culture of Tumour and Immune Cells for More Predictive Infiltration Studies and Immunotherapy Drug Screening.
Palama M, Aiello M, Scaglione S
Methods Mol Biol. 2024; 2782:147-157.
PMID: 38622399
DOI: 10.1007/978-1-0716-3754-8_11.
Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies.
Safaei S, Fadaee M, Farzam O, Yari A, Poursaei E, Aslan C
Breast Cancer Res. 2024; 26(1):57.
PMID: 38553754
PMC: 10981336.
DOI: 10.1186/s13058-024-01810-z.
Optimising IL-2 for Cancer Immunotherapy.
Sprent J, Boyman O
Immune Netw. 2024; 24(1):e5.
PMID: 38455463
PMC: 10917570.
DOI: 10.4110/in.2024.24.e5.
Oncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential Inhibitors.
Eldeen M, Mamdouh F, K Abdulsahib W, Eid R, Alhanshani A, Shati A
Pharmaceuticals (Basel). 2024; 17(2).
PMID: 38399367
PMC: 10891693.
DOI: 10.3390/ph17020152.
Malinzi, a traditional medicinal plants: Comprehensive review of botany, medical application, chemical composition, and pharmacology.
Zhai R, Fu X, Ren X
Heliyon. 2024; 10(3):e24986.
PMID: 38333853
PMC: 10850416.
DOI: 10.1016/j.heliyon.2024.e24986.
Reversing cancer immunoediting phases with a tumor-activated and optically reinforced immunoscaffold.
Li X, Liang X, Fu W, Luo R, Zhang M, Kou X
Bioact Mater. 2024; 35:228-241.
PMID: 38333614
PMC: 10850754.
DOI: 10.1016/j.bioactmat.2024.01.026.
Characterization of CD4 and CD8 T cells responses in the mixed lymphocyte reaction by flow cytometry and single cell RNA sequencing.
Mangelinck A, Dubuisson A, Becht E, Dromaint-Catesson S, Fasquel M, Provost N
Front Immunol. 2024; 14:1320481.
PMID: 38283342
PMC: 10820991.
DOI: 10.3389/fimmu.2023.1320481.
Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.
Garcia-Dominguez D, Lopez-Enriquez S, Alba G, Garnacho C, Jimenez-Cortegana C, Flores-Campos R
Int J Mol Sci. 2024; 25(2).
PMID: 38256268
PMC: 10816838.
DOI: 10.3390/ijms25021195.
Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management.
Gorensek R, Kresnik M, Takac I, Rojko T, Sobocan M
Breast Cancer (Dove Med Press). 2023; 15:773-783.
PMID: 37936879
PMC: 10627091.
DOI: 10.2147/BCTT.S399157.
Cyclin Dependent Kinase Inhibitor 2A Genetic and Epigenetic Alterations Interfere with Several Immune Components and Predict Poor Clinical Outcome.
Soltan M, Alhanshani A, Shati A, Alqahtani Y, Alshaya D, Alharthi J
Biomedicines. 2023; 11(8).
PMID: 37626750
PMC: 10452213.
DOI: 10.3390/biomedicines11082254.